CALL - SPRINTER OPEN END - NOVO-NORDISK B | Real-time Bid/Ask 11:10:15 03/06/2024 BST | ||
| 20.78 EUR / 20.79 EUR | +1.49% |
|
| 1 month | +4.07% | ||
| 3 months | +10.94% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 03/06/24 | 20.84 | +1.76% |
| 31/05/24 | 20.48 | -0.58% |
| 30/05/24 | 20.6 | +0.78% |
| 29/05/24 | 20.44 | -0.87% |
| 28/05/24 | 20.62 | -1.39% |
Delayed Quote Börse Stuttgart
Last update June 03, 2024 at 07:11 am
More quotesStatic data
| Product type | Warrant Knock-Out senza Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| WKN | VA95JD |
| ISIN | DE000VA95JD6 |
| Date issued | 26/11/2018 |
| Strike | 149.2 kr |
| Maturity | Unlimited |
| Parity | 5 : 1 |
| Emission price | 0.15 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 20.93 € |
|---|---|
| Lowest since issue | 0.1 € |
| Spread | 0.01 € |
| Spread % | 0.05% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
927.3
DKK
Average target price
917.2
DKK
Spread / Average Target
-1.09%
- Stock Market
- Certificates
- Certificat
